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Technological advances in mass spectrometry instrumentation and proteomics methodologies 
are moving the field of clinical proteomics towards the analysis of large numbers of patient 
samples in a reasonable time. The Special Issue ‘Clinical proteomics’ reviews the current 
proteomic work flow from biological sample preparation to clinical exploitation with samples 
collected from human body fluids, tissues or isolated cells, and highlights the trend towards 
integrated omics approaches for clinical usage.  
Hernandez-Valladaras and colleagues [1] provide an overview of sample processing methods 
for acute myeloid leukemia cells (AML) harvested in bone marrow and peripheral blood from 
patients suffering from hematopoietic disease. AML biomarkers are promising targets for 
diagnostic and prognostic purposes enabling individual treatment regimens and identifying 
patients requiring bone marrow transplant. The review article compares the performance of 
urea-based lysis methods versus the filter-aided sample preparation (FASP) procedures and 
concludes that FASP-based procedures outperform standard in-solution digestion procedures 
and recommends to explore sample preparation methods for other cancer cells before 
analysing large patient cohorts. Peptide fractionation of AML protein digests is encouraged 
for obtaining in depth proteomes and phosphoproteomes by combining FASP with C18 
STAGE tip fractionation steps and with IMAC as phosphopeptide enrichment step.  
Sample processing and bioanalytical workflows dedicated to phosphoproteome analysis of 
traditional human biological fluids such as serum/plasma, urine, cerebrospinal fluid (CSF), 
saliva and broncoalveolar lavage fluid are discussed by Giorginanni and Beranova-Giorgianni 
[2], together with an overview in protein depletion methods for the detection of low abundant 
biomarkers. Multiple Affinity Removal System (MARS) is a popular immuno-affinity 
column for specific removal of abundant proteins, despite the possibility of depleting some 
off-target proteins. ProteoMiner protein enrichment technology is another depletion approach 
that allows for detection of equal protein amounts within a complex protein sample by 
employing a bead-based library of combinatorial peptide ligands to concentrate low 
abundance proteins to specific peptide ligands and dilute high abundance proteins by washing 
off excess protein after saturating specific peptide ligands. The authors review 
phosphoproteome applications for a variety of diseases (various cancers and neurological 
disorders) and conclude that clinical applications are largely unexplored and partly 
complicated by the plethora of bioanalytical workflows currently in use, and they foresee a 
move to simpler workflows relying on ‘single shot’ analyses with extended liquid 
chromatography (LC) gradients.  
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Sample handling procedures of non-traditional human samples such as ear wax, saliva, 
vitreous humor, aqueous humor, tears, nipple aspirate fluid, breast milk / colostrum, cervical-
vaginal fluid, nasal secretions, bronco-alveolar lavage fluid, and stools for the utilization in 
quantitative proteomic studies for diagnostic and disease treatment purposes are reviewed by 
Licier et al. [3]. The article provides an excellent overview of various protein labelling 
methods for quantitative proteomics and recent clinical research work conducted with the 
non-traditional samples.  
Trenchevska et al. [4] discuss a targeted sample processing approach for intact proteins 
isolated from human samples by Mass Spectrometric Immunoassay (MISA), the mass 
spectrometric equivalent of the Enzyme-Linked Immunosorbent Assay (ELISA). In this assay 
microcolumns are immobilised with antibodies to capture target proteins from complex 
biological samples that are detected by MALDI-TOF MS or ESI MS after rinsing the affinity 
pipette to remove non-specifically bounded proteins. Quantitative MISA experiments require 
co-immobilisation of an internal reference standard with an antibody towards the target 
protein that is exogenous to human body fluids, for example directed against protein 
derivatives (His-tagged proteins), or directed against homologues proteins from other animal 
species. Exogenous protein is spiked into samples as protein standard for absolute 
quantification. The authors focus on MISA applications of clinically significant 
proteoisoforms arising from alternative splicing, single nucleotide polymorphisms (SNPs) 
and post translational modifications. Some of the well-established disease biomarkers such as 
cystatin C, prostate-specific antigen and cardiac troponin exist in several forms in vivo. The 
potential of this method is demonstrated by published MISA experiments for more than 20 
protein targets, where the authors highlight their own contributions showing detection of 
Serum amyloid A (SAA) protein isoforms from individuals expressing various polymorphic 
variants as distinct peaks in MALDI-TOF mass spectra.  
Apolipoproteins have also been shown to exist in vivo in several proteoisoforms, which are 
involved in lipid metabolism, and are associated with cardiovascular diseases, type 2 diabetes 
and Alzheimer Disease (AD). Martins [5] argues that the observed variation in the detection 
of Apo E isoforms by clinical proteomics of various proteins in body fluids, originates from 
biological variation rather than from technical variation. Complementary technologies 
utilising genomics and lipidomics are therefore crucial for early stage diagnosis by revealing 
abnormalities in cholesterol levels and lipoprotein metabolism that are associated with 
cognitive and behavioral symptoms in later AD stages. Clinical genomics testing for Apo E is 
important for diagnosis avoiding errors by proteomics testing from the biological variation in 
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amyloid beta and Apo E protein expression. Clinical lipidomics testing of plasma, tissue and 
CSF samples have provided reproducible results for the diagnosis of various neurological 
diseases including AD, which are also linked to chronic diseases. These complementary 
diagnostic tests suggest that nuclear receptors crucially determine the links between insulin 
resistance, chronic disease and AD, such as the downregulation of the calorie-sensitive anti-
aging nuclear receptor Sirt1 in early stage of AD. The link between cholesterol and 
developing AD opens the door for treatment with nutritional diets maintaining cholesterol 
homeostasis. Nutritional proteomics research showed that AD plasma biomarkers are 
regulated by low fat diets through activation of Sirt1 preventingamyloid beta aggregation and 
induced inflammation. 
The notion that detailed insights in cellular homeostasis and disease progression are 
generated from studies applying clinical proteomics with complementary omics technologies 
inspired Bosman for outlining the current perspective of red blood cell (RBC) homeostasis by 
integrating proteome with metabolome data [6]. Comparative proteomics studies have 
generated erythrocyte protein inventories and provided new insights in mechanisms 
controlling red blood cell morphology under pathological conditions. Protein kinase activities 
and signalling networks regulate pathology-associated changes in phosphorylation status of 
erythrocyte cytoskeleton proteins, such as band 3, and RBC membrane structure. Proteomics 
of the erythrocyte cytosolic fraction identified not only metabolic enzymes involved in 
glycolysis and pentose phosphate pathway but also protein-repair enzymes. These enzymes 
are thought to be assembled in multiprotein complexes regulating oxygen transport, 
metabolism, anti-oxidant activity and protein breakdown. Metabolomics data suggests that 
CO2 concentrations are also associated with the multiprotein complexes besides oxygen. The 
combination of proteome and metabolome data alludes to a mechanism with central roles for 
molecular interactions at the red cell surface regulating cell shape, deformability, cell survival, 
and metabolism with oxygen and CO2 transport. Support for this proposed mechanism comes 
from observations that glycolysis and the pentose phosphate pathway are regulated by 
oxygen-driven interactions of key enzymes with the membrane, and that binding between 
cytoskeleton and membrane is controlled by oxygen-mediated interaction between band 3 
and ankyrin. Recent studies further establish relations between metabolic changes and 
erythrocyte pathologies, which are likely caused by changes in membrane-associated protein 
complexes.  
The holistic view of the utilization of complementary mass spectrometry-based technologies 
in personalized proteomics for clinical diagnosis and treatment is seen by Duarte and Spencer 
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[7] as the future for personalized medicine. Genomics information alone is insufficient for 
diagnosing multifactorial diseases such as AD by the inherent inability in gathering all 
information that predict physiological states of patients, such as protein expression patterns, 
protein-protein interactions, PTMs and metabolites. Current limitations for personalized 
proteomics in clinical practice are technological complexity of the analyses involved and lack 
of standardisation for sample processing procedures [1–4] and mass spectrometry 
methodology [1–3,7]. Furthermore, translation of proteomics-based biomarker discovery 
research into the clinic has been limited by failures in the validation phase in testing large 
patient cohorts. More integration of biomarker discovery phase research with clinical studies 
will lead to the implementation of validated biomarker assays in clinical practice and move 
clinical proteomics out of its infancy.  
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